Investigating a specific receptor in pituitary tumors to improve treatment planning.
Official title: Somatostatin Receptor 2 Expression in Pituitary Neuroendocrine Tumors as a Basis for PET/MRI guided Subtype Stratification and Radiotherapy Planning
Funded at Weill Medical Coll of Cornell Univ · NIH-11115111 · Data updated 2026-11-12
This study is looking at a common type of brain tumor called pituitary neuroendocrine tumors to see how a specific receptor can help doctors better understand the disease after surgery, with the goal of improving radiation therapy for patients who still have tumor left.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $235,707 |
| NIH project number | 1R21CA289111-01A1 |
| Project ID | NIH-11115111 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pituitary neuroendocrine tumors who have residual disease after surgery.
✕Less likely to help
Patients with pituitary tumors that have been completely removed or those who do not express somatostatin receptor 2 may not benefit from this research.
What this research studies
This research focuses on pituitary neuroendocrine tumors (pitNET), which are a common type of brain tumor. It aims to better understand the expression of somatostatin receptor 2 (SSTR2) in these tumors, which can help in accurately identifying the extent of the disease after surgery. By using advanced imaging techniques like PET/MRI, the study seeks to improve the planning of radiation therapy for patients who have not been cured by surgery. This approach could lead to more effective treatment options for patients with residual tumors.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with pituitary tumors by enhancing the accuracy of tumor targeting during radiation therapy.
How similar studies have gone: Previous research has shown promising results using similar imaging techniques to improve treatment planning for brain tumors, indicating potential success for this approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Ivanidze, Jana — Weill Medical Coll of Cornell Univ
- Study coordinator: Ivanidze, Jana
Related research
Other NIH-funded projects on the same topics.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A computer program helps plan radiation therapy for cervical and head-and-neck cancer patients to make treatments faster and more accurate.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A United Kingdom study is testing AI software that helps plan radiotherapy for cervical and head-and-neck cancer patients to save time and reduce the workload for clinicians in low-resource settings.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK research team is testing an AI-based software to automatically outline cancer areas and plan radiation beams to speed up treatment for cervical and head-and-neck cancers in LMICs.
-
AI-Powered Radiotherapy Planning for Cervical and Head & Neck Cancer
A new AI tool helps plan radiation therapy for cervical and head-and-neck cancers to save time and reduce the need for specialized staff.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK study from University College London uses AI to plan radiotherapy for cervical and head-and-neck cancers to save time and reduce the need for specialized staff, aiming to help patients in LMICs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.